S Pavel Hroboň M, Škodová Magdalena, Kučová Petra, Votápková Jana
Vnitr Lek. 2020 Spring;66(5):69-71.
Prevalence of type 2 diabetes in the Czech Republic can be estimated from data reported by health care providers either to the statistical office or to health insurers. The latter include both diagnosis and prescribed drugs. Patient classification to a certain chronic condition based on consumption of drugs (Pharmacy-based Cost Groups classification) has been used in the Czech Republic for the purpose of redistribution of collected funds among health insurers since the beginning of 2018. This article compares prevalence of diabetes estimated from statistical data and from data reported to health insurers, and discusses current and future advantages and disadvantages of all methodologies. Diagnoses reporting in outpatient care are considered to be inaccurate, on the other hand peroral antidiabetics do not seem to be prescribed to all indicated patients. The appropriate approach to prevalence estimation from data reported to health insurers is becoming even more important after the creation of National Diabetes Register based on insurance data and the related abatement of direct reporting to the statistical office.
捷克共和国2型糖尿病的患病率可根据医疗服务提供者向统计局或健康保险公司报告的数据进行估算。后者包括诊断和处方药。自2018年初以来，捷克共和国一直采用基于药品消费的患者分类（基于药房的成本组分类），以便在健康保险公司之间重新分配所筹集的资金。本文比较了根据统计数据和向健康保险公司报告的数据估算出的糖尿病患病率，并讨论了所有方法当前和未来的优缺点。门诊护理中的诊断报告被认为不准确，另一方面，口服抗糖尿病药物似乎并未开给所有有指征的患者。在基于保险数据创建国家糖尿病登记册以及减少向统计局的直接报告之后，从向健康保险公司报告的数据估算患病率的适当方法变得更加重要。
